Corrective and preventive action (CAPA) is a concept of good manufacturing practices (GMP). CAPA focuses on a systematic investigation of discrepancies (failures and/or deviations) in an attempt to prevent a recurrence. To ensure the effectiveness of corrective and preventive actions, a systematic failure investigation is used to determining the corrective and preventive actions taken. CAPA is part of a general quality management system. CAPA is of paramount importance to the FDA. According to FDA documents, CAPA represents 30-50% of FDA-483 forms issued for non-compliance.

Any product presented on the market can receive a "market complaint" if the product does not meet the customer's requirements or, possibly, for any critical defect. When it comes to medications, they are expected to be of the highest quality and effective. The product is safe and effective, provided that the medication meets certain important criteria in relation to parameters such as safety, personality, strength, purity, and quality. In everyday life, medication can also receive a complaint from the market. Unlike any other product, here, in this case, the user is a patient and, therefore, its influence and consequences are very serious. The patient already suffers from a serious illness or illness depending on the state of the disease and, therefore, the medicine is expected to be safe to use, effective (or) of the best quality, as expected by the patient community. All personnel involved in the production of the product, it's testing and launch are responsible for the quality. A solid quality assurance system (QA) with a commitment to plant-level quality will have a positive effect on product quality, which will result in a product with zero defects. A manufacturing unit with sincere quality equipment can deliver a defect-free medication to patients. Finally, a strong regulatory body to implement the rules and regulations, periodically following the guidelines, will help the patient get the right medications at the right time.